Table 1 Summary of the literature review
Characteristic | ||
|---|---|---|
Age (years) | Mean | 30.22 |
Median | 30 | |
Range | 30–70 | |
Male | 63.00% | |
Primary site | Cervical | 11.1% |
Thoracic | 5.6% | |
Lumber | 29.6% | |
Sacral | 0 | |
Thoracolumber | 27.8% | |
Lumbosacral | 16.7% | |
Cervicothoracic | 7.4% | |
Thoracolumbosacral | 1.9% | |
Year of diagnosis | 1997–2001 | 9.3% |
2002–2006 | 9.3% | |
2007–2011 | 25.9% | |
2012–2016 | 33.3% | |
2017–2021 | 20.4% | |
2022 | 1.9% | |
Presentation | Pain | 72.2% |
Motor deficits | 38.9% | |
Sensory deficits | 24.1% | |
Sphincter disturbances | 14.8% | |
NA | 14.8% | |
Resection | GTR | 44.4% |
STR | 38.9% | |
Biopsy | 1.9% | |
NA | 14.8% | |
Adjuvant therapy | Chemotherapy alone | 11.1% |
Radiotherapy alone | 3.7% | |
Chemoradiotherapy | 63% | |
No | 5.6% | |
NA | 16.7% | |
CD99 | Positive | 83.3% |
NA | 16.7% | |
Synaptophysin | Positive | 31.5% |
Negative | 14.8% | |
NA | 53.7% | |
EWSR1 gene translocations | t(11;22) | 38.9% |
t(21;22) | 1.9% | |
Unspecified | 7.4% | |
Negative | 1.9% | |
NA | 50% | |
Outcome | AWD | 22.2% |
DOD | 20.4% | |
NED | 35.2% | |
NA | 22.2% | |
Recurrence | Positive | 38.9% |
Negative | 29.6% | |
NA | 31.5% | |